Announcements
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
As of last trade, Verrica Pharmaceuticals Inc (1NE:DUS) traded at 6.77, 11.17% above the 52 week low of 6.09 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.78 |
---|---|
High | 6.78 |
Low | 6.77 |
Bid | 6.75 |
Offer | 7.00 |
Previous close | 6.63 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.42m |
Free float | 20.49m |
P/E (TTM) | -- |
Market cap | 318.15m USD |
EPS (TTM) | -1.75 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 11:30 BST.
More ▼